Mequinol
CAS 150-76-5
Mequinol (CAS 150-76-5) is a Phase 4 pharmaceutical compound with 1 bioactivity target and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | GI50 | 77723.96553571429 nM | 56 | - |
| - | Potency | 19565.53 nM | 9 | - |
| - | IC50 | 19976.309999999998 nM | 1 | - |
| - | AC50 | 15848.9 nM | 1 | - |
| Tyrosinase Enzyme |
INHIBITOR | - | - | Homo sapiens |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Mequinol used for in pharmaceutical contexts?
Mequinol (CAS 150-76-5) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Mequinol?
No adverse-event association or SIDER side-effect rows are rendered for Mequinol in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Mequinol also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for P-HYDROXYANISOLE with EU status "restricted".
What clinical phase is Mequinol in?
Mequinol is rendered with ChEMBL max phase 4 (approved).
What bioactivity targets are documented for Mequinol?
Mequinol has 5 bioactivity rows in this page query. Rendered target entries include Tyrosinase.